Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Chimeric Therapeutics (CHM) releases two CLTX CAR T abstracts showing positive results from its phase one clinical trial
  • The clinical data comes from an ongoing phase one study of four patients with recurrent or progressive glioblastoma
  • Following treatment, the patients showed a disease control rate of 75 per cent, with three out of the four patients returning a best response of stable disease and no dose limiting toxicity
  • The CLTX CAR T phase one clinical trial is currently in progress at a single site in California with plans to expand to a multi-site trial in 2022
  • Chimeric Therapeutics last traded at 32 cents per share on November 12

Chimeric Therapeutics (CHM) has released two CLTX CAR T abstracts which show positive results from its phase one clinical trial.

The two abstracts will be presented at the Society for Neuro-Oncology 27th annual scientific meeting on November 19.

The first abstract, ‘Clinical evaluation of chlorotoxin-directed CAR T cells for patients with recurrent glioblastoma’, provided insight into the initial clinical data for CLTX.

The second, ‘Exploration of a novel toxin-incorporating CAR T cell: how does chlorotoxin recognise glioblastoma cells?’ expanded on the translational understanding of Chlorotoxin (CLTX) activity.

The clinical data released in the first abstract was from an ongoing CLTX CAR T phase one clinical trial in patients with recurrent or progressive glioblastoma. The data focused on four patients who were each treated with Chimeric’s formulation.

Following treatment, the patients showed a disease control rate of 75 per cent, with three out of the four patients returning a best response of stable disease. The CLTX CAR T cells were generally well tolerated and none of the patients experienced a dose limiting toxicity.

Chimeric’s CEO and Managing Director Jennifer Chow said the initial data was highly encouraging as it demonstrated that CLTX CAR T cells were eliciting disease control in recurrent glioblastoma even at the lowest, sub-therapeutic dose level.

“Achieving disease control in three of the four patients treated at this first dose level, along with the generally well tolerated safety profile that was demonstrated, provides us with great enthusiasm for progressing the trial through the higher dose levels and dual routes of administration,” Ms Chow said.

The CLTX CAR T phase 1 clinical trial is currently in progress at a single site in California with plans to expand to a multi-site trial in 2022.

Chimeric Therapeutics last traded at 32 cents per share on November 12.

CHM by the numbers
More From The Market Herald
Magnis Energy Technologies (ASX:MNS) - Chairman, Frank Poullas

" Magnis Energy (ASX:MNS) refutes allegations it engaged an alleged ‘drug boss’

Magnis Energy (MNS) has refuted claims it is “hooked up” with an alleged drug boss, calling the assertions false.

" Cannindah Resources (ASX:CAE) updates copper results from its namesake project

Cannindah Resources (CAE) has published the latest assay results from drilling at its Mt Cannindah Project in central Queensland.

" West Cobar Metals (ASX:WC1) completes drilling at Bulla Park

West Cobar Metals (WC1) has completed a phase one diamond drilling program at its Bulla Park project in New South Wales.

" CD Private Equity Funds Series releases half-year updates

The CD Private Equity Fund Series has released its latest half-year update for all three of its ASX-listed funds.